Firm (s)

Deal

Value

Client

Lead lawyer(s)

Chen & Co

Initial public offering of Shanghai Fosun Pharmaceutical Group Co Ltd

$509 million

Shanghai Fosun Pharmaceutical Group Co Ltd

 Haoxiong Jiang,
Spring Qin Zhang and
Jie Cheng

Clifford Chance

Global medium-term note programme establishment of SK Telecom, and a subsequent issuance of notes under the programme

$700 million

1.Barclays

2.BofA Merrill Lynch

3.Credit Suisse

4.Deutsche Bank

5.HSBC

6.UBS

Hyun Kim

Clifford Chance

Global medium-term note programme establishment of NongHyup Bank, and a subsequent issuance of notes under the programme

$500 million

1.BNP Paribas

2.Crédit Agricole CIB

3.HSBC

4.Morgan Stanley

5.UBS

Hyun Kim and Matt Fairclough

Clifford Chance

Global medium-term note programme establishment of Korea Hydro & Nuclear Power Co, and a subsequent issuance of notes under the programme

$750 million

1.Citigroup Global Markets Inc

2.Deutsche Bank AG (SG branch)

3.Goldman Sachs International

4.Merrill Lynch International

5.Samsung Securities Co Ltd

Hyun Kim

Clifford Chance

Ten-year bancassurance agreement with Allianz SE (Singapore) to distribute Allianz life insurance products across Asia

$128.5 million

HSBC

Alex Erasmus and Amy Ho

Clifford Chance

SK Telecom’s block trade of Posco shares

$400 million

Morgan Stanley

Hyun Kim

Grandall Law Firm

Initial public offering of Shanghai Fosun Pharmaceutical Group Co Ltd

$509 million

1.UBS AG

2.China International Capital Corporation

3.J.P. Morgan Securities (Asia Pacific) Ltd

4.Deutsche Bank AG

5.Agricultural Bank of China International

6.Haitong International

Herbert Smith Freehills

Initial public offering of Shanghai Fosun Pharmaceutical Group Co Ltd

$509 million

1.UBS AG

2.China International Capital Corporation

3.J.P. Morgan Securities (Asia Pacific) Ltd

4.Deutsche Bank AG

5.Agricultural Bank of China International

6.Haitong International

Gary Lock and Kevin Roy

Morrison & Foerster

Initial public offering of Shanghai Fosun Pharmaceutical Group Co. Ltd

$509 million

Shanghai Fosun Pharmaceutical Group Co Ltd

Gregory Wang, Ven Tan and John Moore